Form 10-Q · Quarterly report
Idexx Laboratories 10-Q, filed Aug 4, 2026
- Filed
- CIK
- 0000874716
- Accession no.
- 0000874716-26-000123
Summary
Idexx Laboratories' second-quarter 2026 revenue rose 9.7% to $1.22 billion and organic revenue growth was 9.0%, while income from operations climbed to $425.6 million from $373.0 million a year earlier. The company said current global conflicts, including hostilities in the Middle East, could further disrupt energy markets, fuel prices, transportation networks, and supply chains, potentially affecting operating costs and demand.
Key points
- Total Company revenue was $1,216.6 million in the three months ended June 30, 2026, up 9.7% from $1,109.5 million a year earlier, with organic revenue growth of 9.0%.
- Companion Animal Group revenue rose 9.4% to $1,118.2 million, with organic growth of 8.7%, driven by recurring diagnostics volume and price gains and partly offset by lower placements of the IDEXX inVue Dx Analyzer.
- Income from operations was $425.6 million in the second quarter of 2026, compared with $373.0 million a year earlier; CAG segment income from operations was $393.3 million.
- For the six months ended June 30, 2026, total Company income from operations was $788.2 million, up from $689.6 million a year earlier.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management’s Discussion Business Overview We develop, manufacture, and distribute products and provide services primarily for the companion animal veterinary, livestock, poultry and dairy, and water testing sectors. We also manufacture and sell human medical point-of-care diagnostic products. Our primary products and services are: •Point-of-care veterinary diagnostic products, comprised of instruments, consumables, and rapid assay test kits; •Veterinary reference laboratory diagnostic and consulting services; •Practice management systems, software and diagnostic imaging systems and services used by veterinarians; …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.